Safety and Clinical Activity of ThisCART22 in Patients With r/r Non-Hodgkin's B Cell Lymphoma

Inclusion Criteria: 1. Age 18-70 years old, no gender and race limited; 2. Estimated life expectancy \> 12 weeks deemed by investigator； 3. CD22 were positive by histopathology and/or cytology diagnosis； 4. Patients with relapsed and/or refractory non-Hodgkin's B cell lymphoma (r/r B-NHL)； 5. Relevant indicators for disease or assessment within 4 weeks after the last treatment; 6. Quality of Life Score (KPS) \>50%； 7. Subject has adequate organ function at screening, cardiac ejection fraction ≥ 40%, no evidence of pericardial effusion as determined by an echocardiogram (ECHO); serum ALT/ AST \<3 upper limit of normal (ULN); bilirubin\<2.0 mg/dl; serum creatinine ≤1.6 mg/dl and/or BUN ≤ 1.5 mg/dl; 8. No remission or relapse after hematopoietic stem cell transplantation or autologous somatic immunotherapy; 9. Unsuitable conditions for stem cell transplantation; 10. Signed informed consent form (ICF). Exclusion Criteria: 1. Women in pregnancy or lactation; 2. In active infection including hepatitis B, hepatitis C, HIV, or other fatal viral and bacterial infection； 3. The absolute count of nonprimary neutrophil \< 0.75×10\^9/L or platelet count \< 50×10\^9/L; 4. Abnormal vital signs and failure to cooperate with examination; 5. Patients with mental or psychological diseases who cannot cooperate with treatment and efficacy evaluation; 6. Highly allergic constitution or history of severe allergy; 7. Patients with systemic infection or severe local infection requiring anti-infection treatment; 8. Patients with severe autoimmune diseases; 9. Presence of any other conditions that are unsuitable for this study as judged by the investigator.